Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/infdis/jiaa518 http://scihub22266oqcxt.onion/10.1093/infdis/jiaa518 32785649!7454712!32785649     free     free     free       J+Infect+Dis 2020 ; 222 (12): 1946-1950 Nephropedia Template TP {{tp|p=32785649|t=2020. COVID-19 Vaccines: Should We Fear ADE?|pdf=|usr=}}{{32785649}} gab.com Text COVID-19 Vaccines: Should We Fear ADE JO: J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32785649 #FOAvip Might COVID-19 vaccines sensitize humans to antibody-dependent enhanced (ADE) breakthrough infections? This is unlikely because coronavirus diseases in humans lack the clinical, epidemiological, biological, or pathological attributes of ADE disease exemplified by dengue viruses (DENV). In contrast to DENV, SARS and MERS CoVs predominantly infect respiratory epithelium, not macrophages. Severe disease centers on older persons with preexisting conditions and not infants or individuals with previous coronavirus infections. Live virus challenge of animals given SARS or MERS vaccines resulted in vaccine hypersensitivity reactions (VAH), similar to those in humans given inactivated measles or respiratory syncytial virus vaccines. Safe and effective COVID-19 vaccines must avoid VAH. Twit Text FOAVip COVID-19 Vaccines: Should We Fear ADE ????J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32785649 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32785649 #FOAvip English Wikipedia <ref>{{Cite pmid|32785649}}</ref> COVID-19 Vaccines: Should We Fear ADE? #MMPMID32785649 Halstead SB; Katzelnick L J Infect Dis 2020[Nov]; 222 (12): 1946-1950 PMID32785649show ga Might COVID-19 vaccines sensitize humans to antibody-dependent enhanced (ADE) breakthrough infections? This is unlikely because coronavirus diseases in humans lack the clinical, epidemiological, biological, or pathological attributes of ADE disease exemplified by dengue viruses (DENV). In contrast to DENV, SARS and MERS CoVs predominantly infect respiratory epithelium, not macrophages. Severe disease centers on older persons with preexisting conditions and not infants or individuals with previous coronavirus infections. Live virus challenge of animals given SARS or MERS vaccines resulted in vaccine hypersensitivity reactions (VAH), similar to those in humans given inactivated measles or respiratory syncytial virus vaccines. Safe and effective COVID-19 vaccines must avoid VAH. |*Antibody-Dependent Enhancement[MESH] |Animals[MESH] |COVID-19 Vaccines/adverse effects/*immunology[MESH] |COVID-19/*prevention & control[MESH] |Dengue Vaccines/immunology[MESH] |Humans[MESH] |Hypersensitivity/etiology[MESH] |SARS-CoV-2/immunology[MESH]COVID-19 Vaccines: Should We Fear ADE?(epmc).pdf DeepDyve Pubget Overpricing